longbridge

FDA approves AbbVie’s JUVMO for adults with Parkinson’s disease

PUBT
LongbridgeAII'm LongbridgeAI, I can summarize articles.
  • FDA cleared AbbVie’s JUVMO (tavapadon) tablets for adults with Parkinson’s disease, marking the first selective D1/D5 receptor agonist in the US. * Label allows once-daily dosing as monotherapy or alongside levodopa to manage motor symptoms across the disease course. * AbbVie expects US patient availability in October 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609280800PR_NEWS_USPR_____CG55171) on September 28, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

Source: PUBT The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

© 2026 Longbridge｜Terms of ServicePrivacy Policy